The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Open accessAbstract
PURPOSE: Infliximab, a monoclonal antibody, is approved for the treatment of inflammatory diseases at doses that depend on the patient disease population. It was the aim of this study to evaluate its population pharmacokinetics in patients with moderately to severely active ulcerative colitis and characterize patient covariates that affect its disposition in this population. METHODS: Information collected from 482 patients in two randomized, double-blind, placebo-controlled international studies were analyzed using NONMEM. RESULTS: A two-compartment, population pharmacokinetic model described the serum infliximab concentration-time data. Population pharmacokinetic estimates (typical value +/- standard error), based on the final covariate model, were clearance (CL: 0.407 +/- 0.0103 L/day), apparent volumes of distribution in the central (V(1): 3.29 +/- 0.0679 L) and peripheral (V(2): 4.13 +/- 0.16 L) compartments, and intercompartment clearance (Q: 7.14 +/- 0.489 L/day). Infliximab exhibited interindividual variability for CL and V(1) of 37.7% and 22.1%, respectively. Infliximab t(1/2) is approximately 14 days. Covariate analysis showed that V(1) increased as body weight increased, and CL was higher in patients who developed antibodies to infliximab. An additional novel covariate, serum albumin concentration, was found to be inversely and strongly related to infliximab clearance in this population. CONCLUSIONS: The disposition of infliximab in patients with moderately to severely active ulcerative colitis, unlike in rheumatoid arthritis, was not affected by coadministration of immunomodulators and corticosteroids but was related to formation of antibodies to infliximab and, notably, to serum albumin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
Jonsson, E. N., & Karlsson, M. O. (1998) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(98)00067-4 · Cited by 1,002
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Karlsson, M. O., & Savic, R. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100241 · Cited by 541
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Self-citationStability and Performance of a Population Pharmacokinetic Model
Ette, E. I. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04326.x · Cited by 353
Brendel, K., Comets, E., Laffont, C., Laveille, C., & Mentré, F. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9067-5 · Cited by 307
Clinical Pharmacokinetics and Use??of??Infliximab
Klotz, U., Teml, A., & Schwab, M. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00002 · Cited by 261
Kim, J., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.001 · Cited by 208
Ng, C. M., Bruno, R., Combs, D., & Davies, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277075 · Cited by 203
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients
Ternant, D., Aubourg, A., Magdelaine-Beuzelin, C., Degenne, D., Watier, H., Picon, L., & Paintaud, G. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318180e300 · Cited by 188
Gottlieb, A. B., Masuda, S., Ramamurthi, R., Abdulghani, A. A., Romano, P., Chaudhari, U., Dooley, L. T., Fasanmade, A. A., & Wagner, C. L. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.10 · Cited by 153
Self-citationPharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease
Schwab, M. G., & Klotz, U. E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140100-00003 · Cited by 132
The clinical pharmacology of therapeutic monoclonal antibodies
Roskos, L. K., Davis, C., & Schwab, G. M. (2004) · Drug Development Research · doi:10.1002/ddr.10346 · Cited by 112
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
Xu, Z., Seitz, K., Fasanmade, A. A., Ford, J. A., Williamson, P., Xu, W., Davis, H. M., & Zhou, H. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008316886 · Cited by 109
Self-citationSiddiqui, M. A. A., & Scott, L. J. (2005) · Drugs · doi:10.2165/00003495-200565150-00014 · Cited by 83
Pharmacokinetics and Pharmacodynamics of Biotech Drugs
(2006) · Wiley eBooks · doi:10.1002/9783527609628 · Cited by 72
Cited by
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Ureña, S., Lim, M., Lee, Y.-A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203091 · Cited by 606
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Metadata
- Authors
- Fasanmade, A. A., Adedokun, O. J., Ford, J., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2009-09-16
- Volume
- 65
- Issue
- 12
- Pages
- 1211-1228
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2044160586
- Cited by
- 327
- References
- 22
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.